{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:52:02Z","timestamp":1792605122003,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family that is known to be a regulator of B cell signaling. Its B cell-specific expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the treatment of B cell lymphomas and autoimmune diseases. Although CD22 is well documented to be an endocytic receptor, it is believed that after internalization, it is targeted for degradation. We show in this study that CD22 is instead constitutively recycled to the cell surface. We also find that glycan ligand-based cargo is released from CD22 and accumulates intracellularly as CD22 recycles between the cell surface and endosomal compartments. In contrast, Abs to CD22 do not accumulate but remain bound to CD22 and recycle to the cell surface. The results have implications for development of agents that target CD22 as an endocytic receptor for delivery of cytotoxic cargo to B cells.<\/jats:p>","DOI":"10.4049\/jimmunol.1003005","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T22:47:49Z","timestamp":1293058069000},"page":"1554-1563","source":"Crossref","is-referenced-by-count":105,"title":["CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells"],"prefix":"10.1093","volume":"186","author":[{"given":"Mary K","family":"O\u2019Reilly","sequence":"first","affiliation":[{"name":"Department of Chemical Physiology, The Scripps Research Institute , La Jolla, CA, 92037"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Chemical Physiology, The Scripps Research Institute , La Jolla, CA, 92037"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Paulson","sequence":"additional","affiliation":[{"name":"Department of Chemical Physiology, The Scripps Research Institute , La Jolla, CA, 92037"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2025032411013959100_r1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2025032411013959100_r2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1042\/BST0361467","article-title":"Siglecs as positive and negative regulators of the immune system","volume":"36","author":"Crocker","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"2025032411013959100_r3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.7618087","article-title":"A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP","volume":"269","author":"Doody","year":"1995","journal-title":"Science"},{"key":"2025032411013959100_r4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","article-title":"CD22: an inhibitory enigma","volume":"123","author":"Walker","year":"2008","journal-title":"Immunology"},{"key":"2025032411013959100_r5","doi-asserted-by":"crossref","first-page":"44315","DOI":"10.1074\/jbc.M105446200","article-title":"CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1","volume":"276","author":"Otipoby","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r6","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1074\/jbc.M706584200","article-title":"Novel binding site for Src homology 2-containing protein-tyrosine phosphatase-1 in CD22 activated by B lymphocyte stimulation with antigen","volume":"283","author":"Zhu","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r7","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1073\/pnas.0400851101","article-title":"Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact","volume":"101","author":"Collins","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411013959100_r8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nchembio713","article-title":"Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking","volume":"1","author":"Han","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"2025032411013959100_r9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1074\/mcp.M900461-MCP200","article-title":"In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics","volume":"9","author":"Ramya","year":"2010","journal-title":"Mol. Cell Proteomics"},{"key":"2025032411013959100_r10","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1073\/pnas.95.13.7469","article-title":"Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes","volume":"95","author":"Razi","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411013959100_r11","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.4049\/jimmunol.170.7.3534","article-title":"The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction","volume":"170","author":"John","year":"2003","journal-title":"J. Immunol."},{"key":"2025032411013959100_r12","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/MCB.00383-07","article-title":"Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity","volume":"27","author":"Tateno","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"2025032411013959100_r13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(02)00416-8","article-title":"Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization","volume":"17","author":"Stoddart","year":"2002","journal-title":"Immunity"},{"key":"2025032411013959100_r14","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1091\/mbc.e05-01-0025","article-title":"Plasticity of B cell receptor internalization upon conditional depletion of clathrin","volume":"16","author":"Stoddart","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"2025032411013959100_r15","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1073\/pnas.90.8.3236","article-title":"CD22 associates with the human surface IgM-B-cell antigen receptor complex","volume":"90","author":"Leprince","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411013959100_r16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ni1283","article-title":"Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling","volume":"7","author":"Collins","year":"2006","journal-title":"Nat. Immunol."},{"key":"2025032411013959100_r17","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1128\/MCB.00308-06","article-title":"ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling","volume":"26","author":"Grewal","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"2025032411013959100_r18","doi-asserted-by":"crossref","first-page":"27809","DOI":"10.1074\/jbc.273.43.27809","article-title":"Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif","volume":"273","author":"Chan","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r19","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.4049\/jimmunol.154.9.4466","article-title":"Constitutive endocytosis and degradation of CD22 by human B cells","volume":"154","author":"Shan","year":"1995","journal-title":"J. Immunol."},{"key":"2025032411013959100_r20","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res."},{"key":"2025032411013959100_r21","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2009-12-257386","article-title":"In vivo targeting of B-cell lymphoma with glycan ligands of CD22","volume":"115","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"2025032411013959100_r22","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.4049\/jimmunol.177.5.2994","article-title":"High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells","volume":"177","author":"Collins","year":"2006","journal-title":"J. Immunol."},{"key":"2025032411013959100_r23","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1021\/ja077801n","article-title":"On-virus construction of polyvalent glycan ligands for cell-surface receptors","volume":"130","author":"Kaltgrad","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"2025032411013959100_r24","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1021\/ja802008q","article-title":"Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells","volume":"130","author":"O\u2019Reilly","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"2025032411013959100_r25","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Res."},{"key":"2025032411013959100_r26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2008.04.018","article-title":"Newer monoclonal antibodies for hematological malignancies","volume":"36","author":"Castillo","year":"2008","journal-title":"Exp. Hematol."},{"key":"2025032411013959100_r27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.tips.2009.02.005","article-title":"Siglecs as targets for therapy in immune-cell-mediated disease","volume":"30","author":"O\u2019Reilly","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"2025032411013959100_r28","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"key":"2025032411013959100_r29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","article-title":"Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma","volume":"12","author":"DiJoseph","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2025032411013959100_r30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"2025032411013959100_r31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2141.2003.04305.x","article-title":"Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells","volume":"121","author":"Sieber","year":"2003","journal-title":"Br. J. Haematol."},{"key":"2025032411013959100_r32","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.284.5418.1372","article-title":"UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation","volume":"284","author":"Keppler","year":"1999","journal-title":"Science"},{"key":"2025032411013959100_r33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.20011796","article-title":"Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling","volume":"195","author":"Jin","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025032411013959100_r34","first-page":"219","article-title":"Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics","volume":"146","author":"Le","year":"1999","journal-title":"J. Cell Biol."},{"key":"2025032411013959100_r35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1074\/jbc.M406906200","article-title":"Rab13 mediates the continuous endocytic recycling of occludin to the cell surface","volume":"280","author":"Morimoto","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r36","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1210\/mend.13.10.0360","article-title":"Internalization and recycling pathways of the thyrotropin receptor","volume":"13","author":"Baratti-Elbaz","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"2025032411013959100_r37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1083\/jcb.108.2.389","article-title":"Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation","volume":"108","author":"Heuser","year":"1989","journal-title":"J. Cell Biol."},{"key":"2025032411013959100_r38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1091\/mbc.4.12.1251","article-title":"Endosome acidification and receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism involving the receptor\u2019s internalization motif","volume":"4","author":"Johnson","year":"1993","journal-title":"Mol. Biol. Cell"},{"key":"2025032411013959100_r39","doi-asserted-by":"crossref","first-page":"13929","DOI":"10.1074\/jbc.272.21.13929","article-title":"Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling","volume":"272","author":"Presley","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r40","first-page":"227","article-title":"Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia","volume":"42","author":"Kon\u00edkov\u00e1","year":"1995","journal-title":"Neoplasma"},{"key":"2025032411013959100_r41","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood.V87.11.4723.bloodjournal87114723","article-title":"Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22\/CD22L interactions impairs T-cell proliferation","volume":"87","author":"Tuscano","year":"1996","journal-title":"Blood"},{"key":"2025032411013959100_r42","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/eji.1830260610","article-title":"Involvement of p72syk kinase, p53\/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22","volume":"26","author":"Tuscano","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"2025032411013959100_r43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V94.4.1382","article-title":"CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK\/SAPK signaling cascade","volume":"94","author":"Tuscano","year":"1999","journal-title":"Blood"},{"key":"2025032411013959100_r44","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","article-title":"CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo","volume":"177","author":"Haas","year":"2006","journal-title":"J. Immunol."},{"key":"2025032411013959100_r45","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2002-08-2629","article-title":"Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts","volume":"101","author":"Tuscano","year":"2003","journal-title":"Blood"},{"key":"2025032411013959100_r46","doi-asserted-by":"crossref","first-page":"9681","DOI":"10.1016\/S0021-9258(17)44551-0","article-title":"Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents","volume":"258","author":"Ciechanover","year":"1983","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0092-8674(83)90517-2","article-title":"The asialoglycoprotein receptor internalizes and recycles independently of the transferrin and insulin receptors","volume":"32","author":"Ciechanover","year":"1983","journal-title":"Cell"},{"key":"2025032411013959100_r48","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1128\/IAI.02094-05","article-title":"Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides","volume":"74","author":"Avril","year":"2006","journal-title":"Infect. Immun."},{"key":"2025032411013959100_r49","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/blood-2008-11-187302","article-title":"Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response","volume":"113","author":"Carlin","year":"2009","journal-title":"Blood"},{"key":"2025032411013959100_r50","doi-asserted-by":"crossref","first-page":"e1967","DOI":"10.1371\/journal.pone.0001967","article-title":"Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity","volume":"3","author":"Rempel","year":"2008","journal-title":"PLoS One"},{"key":"2025032411013959100_r51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.beha.2006.06.009","article-title":"BL22 and lymphoid malignancies","volume":"19","author":"Kreitman","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2025032411013959100_r52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2009.07939.x","article-title":"Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression","volume":"148","author":"Bogner","year":"2010","journal-title":"Br. J. Haematol."},{"key":"2025032411013959100_r53","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"2025032411013959100_r54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I","article-title":"Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies","volume":"87","author":"Keppler-Hafkemeyer","year":"2000","journal-title":"Int. J. Cancer"},{"key":"2025032411013959100_r55","first-page":"1476","article-title":"Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias","volume":"6","author":"Kreitman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"2025032411013959100_r56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2025032411013959100_r57","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2003-04-1317","article-title":"Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins","volume":"103","author":"Decker","year":"2004","journal-title":"Blood"},{"key":"2025032411013959100_r58","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/1078-0432.CCR-04-1939","article-title":"HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity","volume":"11","author":"Bang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2025032411013959100_r59","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1074\/jbc.M409783200","article-title":"In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin","volume":"280","author":"Ho","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2025032411013959100_r60","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2025032411013959100_r61","doi-asserted-by":"crossref","first-page":"11311","DOI":"10.1073\/pnas.0804851105","article-title":"An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes","volume":"105","author":"Onda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411013959100_r62","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2025032411013959100_r63","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/3\/1554\/61613494\/1003005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/3\/1554\/61613494\/1003005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:43:38Z","timestamp":1743137018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/186\/3\/1554\/7977938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1003005","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2]]},"published":{"date-parts":[[2011,2,1]]}}}